Structural features and cytotoxicity of amyloid oligomers: Implications in Alzheimer's disease and other diseases with amyloid deposits

Progress in Neurobiology

Volumn 99, Issue 3, 2012, Pages 226-245

  Stefani, Massimo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Amyloid; Amyloid cytotoxicity; Amyloid diseases; Amyloid oligomers; Protein aggregation

Indexed keywords

ALPHA LACTALBUMIN; ALPHA SYNUCLEIN; AMYLIN; AMYLOID; AMYLOID BETA PROTEIN; ANDROGEN RECEPTOR; BETA 2 MICROGLOBULIN; CALCITONIN; OLIGOMER; PREALBUMIN; PRION PROTEIN; SERUM AMYLOID A; SUPEROXIDE DISMUTASE;

ALZHEIMER DISEASE; APOPTOSIS; BETA SHEET; BINDING AFFINITY; CELL COMPARTMENTALIZATION; CELL CYCLE REGULATION; CELL INTERACTION; CELL MEMBRANE; CELL VIABILITY; CONFORMATIONAL TRANSITION; CYTOTOXICITY; DNA POLYMORPHISM; GENETIC TRANSCRIPTION; HYDROGEN BOND; HYDROPHILICITY; HYDROPHOBICITY; IONIC STRENGTH; LIPID COMPOSITION; NEUROTOXICITY; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN POLYMERIZATION; REVIEW; SIGNAL TRANSDUCTION; SYMPTOM; TEMPERATURE; THERMODYNAMICS;

ALZHEIMER DISEASE; AMYLOID; ANIMALS; CELL MEMBRANE; HUMANS; NEURONS; PLAQUE, AMYLOID; PROTEIN CONFORMATION;

EID: 84869887960     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2012.03.002     Document Type: Review

References (264)

1. Abad-Rodriguez J., Ledesma M.D., Craessaerts K., Perga S., Medina M., Delacourte A., Dingwall C., De Strooper B., Dotti C.G. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J. Cell Sci. 2005, 167:953-960.
2. Aleardi A.M., Bernard G., Augereau O., Malgat M., Talbot J.C., Mazat J.P., Letellier T., Dachary-Prigent J., Solaini G.C., Rossignol R. J. Bioenerg. Biomembr. 2005, 37:207-225.
3. Anderluh G., Gutierrez-Aguirre I., Rabzelj S., Ceru S., Kopitar-Jerala N., Macek P., Turk V., Zerovnik E. Interaction of human stefin B in the prefibrillar oligomeric form with membranes. Correlation with cellular toxicity. FEBS J. 2005, 272:3042-3051.
4. Apetri A.C., Surewicz K., Surewicz W.K. The effect of disease-associated mutations on the folding pathway of human prion protein. J. Biol. Chem. 2004, 279:18008-18014.
5. Arce F.T., Jang H., Ramachandran S., Landon P.B., Nussinov R., Lal R. Polymorphism of amyloid β peptide in different environments: implications for membrane insertion and pore formation. Soft Matter 2011, 7:5267-5273.
6. Arispe N., Doh M. Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease Aβ(1-40) and (1-42) peptides. FASEB J. 2002, 16:1526-1536.
7. Arispe N., Rojas E., Pollard H.D. Alzheimer's disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminium. Proc. Natl. Acad. Sci. U.S.A. 1993, 89:10940-10944.
8. Azimov R., Azimova R., Hirakura Y., Kagan B.L. Ion channels with different selectivity formed by transthyretin. Biophys. J. 2001, 80:129a.
9. Bader R., Bamford R., Zurdo J., Luisi B.F., Dobson C.M. Probing the mechanism of amyloidogenesis through a tandem repeat of the pi3-sh3 domain suggests a generic model for protein aggregation and fibril formation. J. Mol. Biol. 2006, 356:189-208.
10. Baldwin A.J., Knowles T.P.J., Tartaglia G.G., Fizpatrick A.W., Devlin G.L., Shammas S.L., Waudby C.A., Mossuto M.F., Meehan S., Gras S., Christodoulou J., Antony-Cahill S.J., Barker P.D., Vendruscolo M., Dobson C.M. Metastability of native proteins and the phenomenon of amyloid formation. J. Am. Chem. Soc. 2011, 133:14160-14163.
11. Baskakov I.V., Legname G., Baldwin M.A., Prusiner S.B., Cohen F.E. Pathway complexity of prion protein assembly into amyloid. J. Biol. Chem. 2002, 277:21140-21148.
12. Benvenuti S., Saccardi R., Luciani P., Urbani S., Deledda C., Cellai I., Francini F., Squecco R., Rosati F., Danza G., Gelmini S., Greeve I., Rossi M., Maggi R., Serio M., Peri A. Neuronal differentiation of human mesenchymal stem cells: changes in the expression of the Alzheimer's disease-related gene seladin-1. Exp. Cell Res. 2006, 312:2592-2604.
13. Bero A.W., Yan P., Roh J.H., Cirrito J.R., Stewart F.R., Raichle M.E., Lee J.-M., Holtzman D.M. neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat. Neurosci. 2011, 14:750-757.
14. Berryman J.T., Radford S.E., Harris S.A. Systematic examination of polymorphism in amyloid fibrils by molecular-dynamics simulation. Biophys. J. 2011, 100:2234-2242.
15. Bhatia R., Lin H., Lal R. Fresh and nonfibrillar amyloid β protein(1-42) induces rapid cellular degeneration in aged human fibroblasts: evidence for AβP-channel-mediated cellular toxicity. FASEB J. 2000, 14:1233-1243.
16. Billings L.M., Oddo S., Green K.N., McGaugh J.L., LaFerla F. Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005, 45:675-688.
17. Bitan G., Kirkitadze M.D., Lomakin A., Volles S.S., Benedek G.B., Teplow D.B. Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:330-335.
18. Bokvist M., Lindström F., Watts A., Gröbner G. Two types of Alzheimer's β-amyloid (1-40) peptide membrane interactions: aggregation preventing transmembrane anchoring versus accelerated surface fibril formation. J. Mol. Biol. 2004, 335:1039-1049.
19. Bolognesi B., Kumita J.R., Barros T.P., Esbjorner E.K., Luheshi L.M., Crowther D.C., Wilson M.R., Dobson C.M., Favrin G., Yerbury J.J. ANS binding reveals common features of cytotoxic amyloid species. ACS Chem. Biol. 2010, 5:735-740.
20. Bousset L., Thomson N.H., Radford S.E., Melki R. The yeast prion Ure2p retains its native alpha-helical conformation upon assembly into protein fibrils in vitro. EMBO J. 2002, 21:2903-2911.
21. 1-42 peptide into stable fibrils of reduced cytotoxicity. J. Biol. Chem. 2008, 283:32471-32783.
22. Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J., Taddei N., Ramponi G., Dobson C.M., Stefani M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002, 416:507-511.
23. Bucciantini M., Calloni G., Chiti F., Formigli L., Nosi D., Dobson C.M., Stefani M. Pre-fibrillar amyloid protein aggregates share common features of cytotoxicity. J. Biol. Chem. 2004, 279:31374-31382.
24. Bucciantini M., Nosi D., Forzan M., Russo E., Calamai M., Pieri L., Formigli L., Quercioli F., Soria S., Pavone F., Savistchenko J., Melki R., Stefani M. Toxic effects of amyloid fibrils on cell membranes: the importance of ganglioside GM1. FASEB J. 2012, 26:818-831.
25. Butterfield A.D., Drake J., Pocernich C., Castegna A. Evidence of oxidative damage in Alzeimer's disease brain: central role for amyloid β-peptide. Trends Mol. Med. 2001, 7:548-554.
26. Bychkova V.E., Pain R.H., Ptitsyn O.B. The molten globule state is involved in the translocation of protein across membranes. FEBS Lett. 1998, 238:231-234.
27. Calamai M., Pavone F.S. Single molecule tracking analysis reveals that the surface mobility of amyloid oligomers is driven by their conformational structure. J. Am. Chem. Soc. 2011, 133:12001-12008.
28. Calamai M., Chiti F., Dobson C.M. Amyloid fibril formation can proceed from different conformations of a partially unfolded protein. Biophys. J. 2005, 89:4201-4210.
29. Campioni S., Mannini B., Pensalfini A., Zampagni M., Parrini C., Evangelisti E., Relini A., Stefani M., Dobson C.M., Cecchi C., Chiti F. The causative link between the structure of aberrant protein oligomers and their ability to cause cell dysfunction. Nat. Chem. Biol. 2010, 6:140-147.
30. Capetillo-Zarate E., Staufenbiel M., Abramowski D., Haass C., Escher A., Stadelmann C., Yamaguchi H., Wiestler .O.D., Thal D.R. Selective vulnerability of different types of commissural neurons for amyloid beta-protein-induced neurodegeneration in APP23 mice correlates with dendritic tree morphology. Brain 2006, 129:2992-3005.
31. Carulla N., Caddy G.L., Hall D.R., Zurdo J., Gairi M., Feliz M., Giralt E., Robinson C.V., Dobson C.M. Molecular recycling within amyloid fibrils. Nature 2005, 436:554-558.
32. Carulla N., Zhou M., Arimon M., Gairi M., Giralt E., Robinson C.V., Dobson C.M. Experimental characterization of disordered and ordered aggregates populated during the process of amyloid fibril formation. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:7828-7833.
33. Caspersen C., Wang N., Yao J., Sosunov A., Chen X., Lustbader J.W., Xu H.W., Stern D., McKhann G., Yan S.D. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J. 2005, 19:2030-2041.
34. Caughey B., Lansbury P.T. Protofibrils, pores, fibrils and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 2003, 26:267-298.
35. Cecchi C., Baglioni S., Fiorillo C., Pensalfini A., Liguri G., Nosi D., Rigacci S., Bucciantini M., Stefani M. Insights into the molecular basis of the differing susceptibility of varying cell types to the toxicity of amyloid aggregates. J. Cell Sci. 2005, 118:3459-3470.
36. Cecchi C., Pensalfini A., Stefani M., Baglioni S., Fiorillo C., Cappadona S., Caporale R., Nosi D., Ruggiero M., Liguri G. Vulnerability to amyloid toxicity depends on the cell-cycle phase in neuroblastoma replicating cells. J. Mol. Med. 2007, 86:197-209.
37. Cecchi C., Rosati F., Pensalfini A., Formigli L., Nosi D., Liguri G., Dichiara F., Morello M., Danza G., Pieraccini G., Peri A., Serio M., Stefani M. Seladin-1/dhcr24 protects neuroblastoma cells against Aβ toxicity by increasing membrane cholesterol content. J. Cell. Mol. Med. 2008, 12:1990-2002.
38. Cerdà-Costa N., Esteras-Chopo A., Avilés F.X., Serrano L., Villegas V. Early kinetics of amyloid fibril formation reveals conformational reorganization of initial aggregates. J. Mol. Biol. 2007, 366:1351-1363.
39. Ceru S., Kokalj S.J., Rabzelj S., Skarabot M., Gutierrez-Aguirre I., Kopitar-Jerala N., Anderluh G., Turk D., Turk V., Zerovnik E. Size and morphology of toxic oligomers of amyloidogenic proteins: a case study of human stefin B. Amyloid 2008, 15:47-59.
40. Chafekar S.M., Baas F., Scheper W. Oligomer-specific Aβ toxicity in cell models is mediated by selective uptake. Biochim. Biophys. Acta 2008, 1782:523-531.
41. Chen Y., Kokholyan N. A single disulfide bond differentiates aggregation pathways of β2-microglobulin. J. Mol. Biol. 2005, 354:473-482.
42. Cheon M., Chang I., Mohanty S., Luheshi L.M., Dobson C.M., Vendruscolo M., Favin G. Structural reorganisation and potential toxicity of oligomeric species formed during the assembly of amyloid fibrils. PLoS Comp. Biol. 2007, 3:1727-1738.
43. Cherny D., Hoyer W., Subramaniam V., Jovin T.M. Double-stranded DNA stimulates the fibrillation of alpha-synuclein in vitro and is associated with the mature fibrils: an electron microscopy study. J. Mol. Biol. 2004, 344:929-938.
44. Chien P., Weissman J.S., DePace A.H. Emerging principles of conformation-based prion inheritance. Annu. Rev. Biochem. 2004, 73:617-656.
45. Chiti F., Dobson C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006, 75:333-366.
46. Chiti F., Dobson C.M. Amyloid formation by globular proteins under native conditions. Nat. Chem. Biol. 2009, 5:15-22.
47. Chiti F., Webster P., Taddei N., Clark A., Stefani M., Ramponi G., Dobson C.M. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:3590-3594.
48. Chiti F., Stefani M., Taddei N., Ramponi G., Dobson C.M. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 2003, 424:805-808.
49. Chromy B.A., Nowak R.J., Lambert M.P., Viola K.I., Chang L., Velasco P.T., Jones B.W., Fernandez S.J., Lacor P.N., Horowitz P., Finch C.E., Krafft G.A., Klein W.L. Self-assembly of Aβ1-42 into globular neurotoxins. Biochemistry 2003, 42:12749-12760.
50. Chung J., Yang H., de Beus M.D., Ryu C.Y., Cho K., Colòn W. Cu/Zn superoxide dismutase can form pore-like structures. Biochem. Biophys. Res. Commun. 2003, 312:873-876.
51. Chung J., Yang H., de Beus M.D., Ryu C.Y., Cho K., Colón W. Cu/Zn superoxide dismutase can form pore-like structures. Biochem. Biophys. Res. Commun. 2003, 312:873-876.
52. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat. Neurosci. 2005, 8:79-84.
53. Cohen A.S., Calkins E. Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature 1959, 183:1202-1203.
54. Colon W., Kelly J.W. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 1992, 31:8654-8660.
55. Conlon I.J., Dunn G.A., Mudge A.W., Raff M.C. Extracellular control of cell size. Nat. Cell Biol. 2001, 3:918-921.
56. Conway K.A., Lee S.-J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T. Acceleration of oligomerization not fibrillization is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease. Implication for pathogenesis and therapy. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:571-576.
57. Craig L.A., Hong N.S., McDonald R.J. Revisiting the cholinergic hypothesis in the development of Alzheimer's disease. Neurosci. Biobehav. Rev. 2011, 35:1397-1409.
58. Crameri A., Biondi E., Kuehnle K., Lutjohann D., Thelen K.M., Perga S., Dotti C.G., Nitsch R.M., Ledesma M.D., Mohajeri M.H. The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and Abeta generation in vivo. EMBO J. 2006, 25:432-443.
59. Danzer K.M., Haasen D., Karow A.R., Moussaud S., Habeck M., Giese A., Kretzschmar H., Hengerer B., Kostka M. Different species of α-synuclein oligomers induce calcium influx and seeding. J. Neurosci. 2007, 271:9220-9232.
60. De Felice F.G., Velasco P.T., Lambert M.P., Viola K., Fernandez S.J., Ferreira S.T., Klein W.L. Aβ oligomers induce neuronal oxidative stress through an N-methyl-d-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem. 2007, 282:11590-11601.
61. DeArmond S.J., McKinlay M.P., Barry R.A. Identification of prion amyloid filaments in scrapie infected brain. Cell 1985, 41:221-235.
62. Dedmon M.M., Patel C.N., Young G.B., Pielak G.J. FlgM gains structure in living cells. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:12681-12684.
63. DeGroot J. Theb AGE of the matrix: chemistry, consequence and cure. Curr. Opin. Pharmacol. 2004, 4:301-305.
64. Demuro A., Mina E., Kayed R., Milton S.C., Parker I., Glabe C.G. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 2005, 280:17294-17300.
65. Deshpande A., Mina E., Glabe C., Busciglio J. Different conformations of amyloid β induce neurotoxicity by distinct mechanisms in human cortical neurons. J. Neurosci. 2006, 26:6011-6018.
66. Dickson D.W. Correlation of synaptic and pathological markers with cognition of the elderly. Neurobiol. Aging 1995, 16:285-298.
67. Ding T.T., Lee S.-J., Rochet J.-C., Lansbury P.T. Annular α-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 2002, 41:10209-10217.
68. Diociaiuti M., Polzim L.Z., Valvo L., Malchiodi-Albedi F., Bombelli C., Gaudiano M.C. Calcitonin forms oligomeric pore-like structures in lipid membranes. Biophys. J. 2006, 91:2275-2281.
69. Divry P., Florkin M. Sur les propriété optiques de l'amyloïde 1927, vol. 97. CR Société de Biologie, Paris, pp. 1808-1810.
70. Dobson C.M. Nature 2003, 426:884-890.
71. Dobson C.M., Karplus M. The fundamentals of protein folding: bringing together theory and experiment. Curr. Opin. Struct. Biol. 1999, 9:2-101.
72. Domanov Y.A., Kinnunen P.K.J. Islet amyloid polypeptide forms rigid lipid-protein amyloid fibrils on supported phospholipid bilayers. J. Mol. Biol. 2008, 376:42-54.
73. Dumoulin M., Camet D., Last A.M., Pardon E., Archer S., Muyldermans S., Wyns L., Matagne A., Robinson C.V., Redfield C., Dobson C.M. Reduced global cooperativity is a common feature underlying the amyloidogenicity of pathogenic lysozyme mutations. J. Mol. Biol. 2005, 346:773-788.
74. Dusa A., Kaylor J., Edridge S., Bodner N., Hong D.P., Fink A.L. Characterization of oligomers during alpha-synuclein aggregation using intrinsic tryptophan fluorescence. Biochemistry 2006, 45:2752-2760.
75. Ehahalt R., Keller P., Haass C., Thiele C., Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 2003, 160:113-123.
76. Ellis R.J. Macromolecular crowding: an important but neglected aspect of the intracellular environment. Curr. Opin. Struct. Biol. 2001, 11:114-119.
77. Engel M.F.M., Yiggitop H.A., Eigersma R.C., Rijkers D.T.S., Liskamp R.M.J., de Kruijff B., Höppener J.W.M., Killian A. Islet amyloid polypeptide inserts into phospholipid monolayers as monomer. J. Mol. Biol. 2006, 356:783-789.
78. Engel M.F., Khemtémourian L., Kleijer C.C., Meeldijk H.J., Jacobs J., Verkeij A.I., de Kruijff B., Killan J.A., Höppener J.K. Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:6033-6038.
79. Evangelisti E., Cecchi C., Cascella R., Sgromo C., Liguri G., Dobson C.M., Chiti F., Stefani M. Physicochemical properties define cell membrane vulnerability to aberrant protein oligomers. J. Cell Sci. 2012, (Epub Feb 17).
80. Fändrich M., Fletcher M.A., Dobson C.M. Amyloid fibrils from muscle myoglobin. Nature 2001, 410:165-166.
81. 2+ release through ryanodine and inositol 1,4,5-triphosphate receptors in the neurotoxic effects induced by the amyloid-beta peptide. J. Neurosci. Res. 2004, 76:872-880.
82. Ferreiro E., Resende R., Costa R., Oliveira C.R., Pereira C.M.F. An endoplasmic-reticulum-specific apoptotic pathway is involved in prion and amyloid-beta peptides neurotoxicity. Neurobiol. Dis. 2006, 23:669-678.
83. Friedreich N., Kekulé Zur Amyloid-frage. Wirchows Arch. Path. Anat. 1859, 16:50.
84. Fujita A., Cheng J., Hirakawa M., Furukawa K., Kusunoki S., Fujimoto T. Gangliosides GM1 and GM3 in the living cell membrane form clusters susceptible to cholesterol depletion and chilling. Mol. Biol. Cell 2007, 18:2112-2122.
85. Geroldi D., Falcone C., Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr. Med. Chem. 2006, 13:1971-1978.
86. Gharibyan A.L., Zamotin V., Yanamandra K., Moskaleva O.S., Margulis B.A., Kostanyan I.A., Morozova-Roche L.A. Lysozyme amyloid oligomers and fibrils induce cellular death via different apoptotic/necrotic pathways. J. Mol. Biol. 2007, 365:1337-13349.
87. Giehm L., Svergun D.I., Otzen D., Vestergaard B. Low-resolution structure of a vesicle disrupting α-synuclein oligomer that accumulates during fibrillation. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:3246-3251.
88. Giorgetti S., Rossi A., Mangione P., Raimondi S., Marini S., Stoppini M., Corazza A., Viglino P., Esposito G., Cetta G., Merlini G., Bellotti V. Beta2-microglobulin isoforms display an heterogeneous affinity for type I collagen. Protein Sci. 2005, 14:696-702.
89. Giorgetti S., Raimondi S., Pagano K., Relini A., Bucciantini M., Corazza A., Fogolari F., Codutti L., Salmona M., Mangione P., Colombo L., De Luigi A., Porcari R., Gliozzi A., Stefani M., Esposito G., Bellotti V., Stoppini M. Effect of tetracyclines on the dynamics of formation and destructuration of β2-microglobulin amyloid fibrils. J. Biol. Chem. 2011, 286:2121-2131.
90. Glabe C.G. Conformation-dependent antibodies target diseases of protein misfolding. Trends Biochem. Sci. 2004, 29:542-547.
91. Glenner G.G., Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 1984, 120:885-890.
92. Goldsbury C., Frey P., Olivieri V., Aebi U., Müller S.A. Multiple assembly pathways underlie amyloid-β fibril polymorphism. J. Mol. Biol. 2005, 352:282-298.
93. Gong Y., Chang I., Viola K.I., Lacor P.N., Lambert M.P., Finch C.E., Krafft G.A., Klein W.I. Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:10417-10422.
94. Gosal W.S., Morten L.J., Hewitt E.W., Smith D.A., Thomson N.H., Radford S.E. Competing pathways determine fibril morphology in the self-assembly of beta2-microglobulin into amyloid. J. Mol. Biol. 2005, 351:850-864.
95. Gouras G.K., Tsai J., Nasslund J., Vincent B., Edgar M., Checler F., Greefiels J.P., Haroutunian V., Buxbaum J.D., Xu H., Greengard P., Relkin N.R. Intraneuronal Aβ accumulation in human brain. Am. J. Pathol. 2000, 156:15-20.
96. Gujiarro J.I., Sunde M., Jones J.A., Campbell I.D., Dobson C.M. Amyloid fibril formation by an SH3 domain. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:4224-4228.
97. Guo Z., Eisenberg D. Runaway domain swapping in amyloid-like fibrils of T7 endonuclease I. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:8042-8047.
98. Hancock R.E.W., Scott M.G. The role of antimicrobial peptides in animal defences. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:8856-8861.
99. Harper J.D., Lansbury P.T. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 1997, 66:385-407.
100. Harris D.A. Cellular biology of prion diseases. Clin. Microbiol. Rev. 1999, 12:429-444.
101. Hartl F.U., Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 2002, 295:1852-1858.
102. He P., Zhong Z., Lindholm K., Berning L., Lee W., Lemere C., Staufenbiel M., Li R., Shen Y. Tumor necrosis factor death receptor signaling cascade is required for amyloid-β protein-induced neuron death. J. Neurosci. 2004, 24:1760-1771.
103. Hepler R.W., Grimm K.M., Nahas D.D., Breese R., Dodson E.C., Acton P., Keller P.M., Yeager M., Wang H., Shughrue P., Kinney G., Joyce J.G. Solution state characterization of amyloid beta-derived diffusible ligands. Biochemistry 2006, 45:15157-15167.
104. Herrup K. Reimagining Alzheimer's disease - an age-based hypothesis. J. Neurosci. 2010, 30:16755-16762.
105. Hirakura Y., Kagan B.L. Pore formation by beta-2-microglobulin: a mechanism for the pathogenesis of dialysis-associated amyloidosis. Amyloid 2001, 8:94-100.
106. Hirakura Y., Carreras I., Sipe J.D., Kagan B.L. Channel formation by serum amyloid A: a potential mechanism for amyloid pathogenesis and host defense. Amyloid 2002, 9:13-23.
107. Homma N. Collagen-binding affinity of B2-microglobulin, a preprotein of hemodialysis-associated amyloidosis. Nephron 1998, 53:37-40.
108. Hoshi M., Sato M., Matsumoto S., Noguchi A., Yasutake K., Yoshida N., Sato K. Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:6370-6375.
109. Hou X., Richardson S.J., Aguilar M.I., Small D.H. Binding of amyloidogenic transthyretin to the plasma membrane alters membrane fluidity and induces neurotoxicity. Biochemistry 2005, 44:11618-11627.
110. Hou X., Parkington H.C., Coleman H.A., Mechler A., Martin L.L., Aguilar M.-I., Small D.H. Transthyretin oligomers induce calcium influx via voltage-gated calcium channels. J. Neurochem. 2007, 100:446-457.
111. Hoyer W., Cherny D., Subramanian V., Jovin T.M. Rapid self-assembly of alpha-synuclein observed by in situ atomic force microscopy. J. Mol. Biol. 2004, 340:127-139.
112. Hsieh H., Boehm J., Sato C., Iwatsubo T., Tomita T., Sisodia S., Malinow R. AMPAR removal underlies Aβ-induced synaptic depression and dendritic spine loss. Neuron 2006, 52:831-843.
113. Huff M.E., Balch W.E., Kelly J.W. Pathological and functional amyloid formation orchestrated by the secretory pathway. Curr. Opin. Struct. Biol. 2003, 13:674-682.
114. Hyun D.-H., Lee M.H., Hattori N., Kubo S.-I., Mizuno Y., Halliwell B., Jenner P. Effect of wild-type or mutant parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome. J. Biol. Chem. 2002, 277:28572-28577.
115. Iijima K., Chiang H.-C., Hearn S.A., Hakker I., Gatt A., Shenton C., Granger L., Leung A., Iijima-Ando K., Zhong Y. Aβ42 mutants with different aggregation profiles induce distinct pathologies in Drosophila. PLoS ONE 2008, 3:1-8.
116. Jahn T.T., Redford S.E. Folding versus aggregation: polypeptide conformations on competing pathways. Arch. Biochem. Biophys. 2008, 469:100-117.
117. Jayakumar R., Jayaraman M., Koteeswarl D., Gomath K. Cytotoxic and membrane perturbation effects of a novel amyloid forming model, peptide poly(leucine-glutamic acid). J. Biochem. (Tokyo) 2004, 136:457-462.
118. Jones E.M., Surewicz W.K. Fibril conformation as the basis of species- and strain-dependent seeding specificity of mammalian prion amyloids. Cell 2005, 121:63-72.
119. Kad N.M., Myers S.L., Smith D.P., Smith D.A., Radford S.E., Thomson N.H. Hierarchical assembly of beta2-microglobulin amyloid in vitro revealed by atomic force microscopy. J. Mol. Biol. 2003, 330:785-797.
120. Kakio A., Nishimoto S.-L., Yanagisawa K., Kozutsumi Y., Matsuzaki K. Interaction of amyloid β-protein with various gangliosides in the raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry 2002, 41:7385-7390.
121. Kakio A., Nishimoto S.-L., Kozutsumi Y., Matsuzaki K. Formation of membrane-active form of amyloid β-protein in raft-like model membranes. Biochem. Biophys. Res. Commun. 2003, 303:514-518.
122. Kamibnski-Schierle G.S., van de Linde S., Erdelyi M., Esbjörnr E.K., Klein T., Rees E., Bertonsini C.W., Dobson C.M., Sauer M., Kaminski C.F. In situ measurements of the formation and morphology of intracellular β-amyloid fibrils by super-resolution fluorescence imaging. J. Am. Chem. Soc. 2011, 133:12905-12908.
123. Kaminski Schierle G.S., van de Linde S., Erdelyi M., Esbjörner E.K., Klein T., Rees E., Bertoncini C.W., Dobson C.M., Sauer M., Kaminski C.F. In situ measurements of the formation and morphology of intracellular β-amyloid fibrils by super-resolution fluorescence imaging. J. Am. Chem. Soc. 2011, 133:12902-12905.
124. Kawahara M. Disruption of calcium homeostasis in the pathogenesis of Alzheimer's disease and other conformational diseases. Curr. Alzemier Res. 2004, 1:87-95.
125. Kawahara M., Kuroda Y., Arispe N., Rojas E. Alzheimer's β-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevation by a common mechanism in a hypopthalamic GnRH neuronal cell line. J. Biol. Chem. 2000, 275:14077-14083.
126. Kayed R., Glabe C.G. Conformation-dependent anti-amyloid oligomer antibodies. Methods Enzymol. 2006, 413:326-344.
127. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanisms of pathogenesis. Science 2003, 300:486-489.
128. Kayed R., Head E., Sarsoza F., Saing T., Cotman C.W., Necula M., Margol L., Wu J., Breydo L., Thompson J.L., Rasool S., Gurlo T., Butler P., Glabe C.G. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegen. 2007, 2:1-18.
129. Kayed R., Pensalfini A., Margol L., Sokolov Y., Sarsoza F., Head E., Hall J., Glabe C. Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J. Biol. Chem. 2009, 284:4230-4237.
130. Kayed R., Canto I., Breydo L., Rasool S., Lukacsovich T., Wu J., Albay R., Pensalfini A., Yeung S., Head E., Marsh L., Glabe C. Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Aβ oligomers. Mol. Neurodegen. 2010, 5:57-66.
131. Kazlauskaite J., Senghera N., Sylvester I., Vénien-Bryan C., Pinheiro T.J.T. Structural changes of the prion protein in lipid membranes leading to aggregation and fibrillization. Biochemistry 2003, 42:3295-3304.
132. Kazlauskaite J., Senghera N., Sylvester I., Vénien-Bryan C., Pinheiro T.J.T. Structural changes of the prion protein in lipid membranes leading to aggregation and fibrillization. Biochem 2003, 42:3295-3304.
133. Knight J.D., Miranker A.D. Phospholipid catalysis of diabetic amyloid assembly. J. Mol. Biol. 2004, 341:1175-1187.
134. Koffie R.M., Meyer-Luehmann M., Hashimoto T., Adams K.W., Mielke M.L., Garcia-Alloza M., Micheva K.D., Smith S.J., Kim M.L., Lee V.M., Hyman B.T., Spires-Jones T.L. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:4012-4017.
135. Koudinov A.L., Koudinova N.V. Cholesterol homeostasis failure as a unifying cause of synaptic degeneration. J. Neurol. Sci. 2005, 229-230:233-240.
136. Kourie J.I. Synthetic C-type mammalian natriuretic peptide forms large cation selective channels. FEBS Lett. 1999, 445:57-62.
137. Kourie J.I. Mechanisms of amyloid β protein-induced modification in ion transport systems: implications for neurodegenerative diseases. Cell. Mol. Neurobiol. 2001, 21:173-213.
138. Kourie J.I., Henry C.L. Ion channel formation and membrane-linked pathologies of misfolded hydrophobic proteins: the role of dangerous unchaperoned molecules. Clin. Exp. Pharmacol. Physiol. 2002, 29:741-753.
139. Kranenburg O., Bouma B., Kroon-Batenburg L.M.J., Reijerkerk A., Wu Y.-P., Voest E.E., Gebbink M.F.B.G. Tissue-type plasminogen activator is a multiligand cross-beta structure receptor. Curr. Biol. 2002, 12:1833-1839.
140. Kumar S., Udgaonkar J.B. Structurally distinct amyloid protofibrils form on separate pathways of aggregation of a small protein. Biochemistry 2009, 48:6441-6449.
141. Kumar S., Walter J. Phosphorylation of amyloid beta (Aβ) peptides - a trigger for formation of toxic aggregates in Alzheimer's disease. Aging (Albany, NY) 2011, 3:803-812.
142. Kyle R.A. Amyloidosis: a convoluted story. Br. J. Haematol. 2001, 114:529-538.
143. Lacor P.N., Buniel M.C., Chang L., Fernandez S.J., Gong Y., Viola K.L., Lambert M., Velasco P.T., Bigio E.H., Finch C.E., Krafft G., Klein W.I. Synaptic targeting by Alzheimer's-related amyloid β oligomers. J. Neurosci. 2004, 24:10191-10200.
144. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., Klein W.L. Diffusible nonfibrillar ligands derived from Aβ are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A. 1998, 93:6448-6453.
145. Langkilde A.E., Vestergaard B. Methods for structural characterization of prefibrillar intermediates and amyloid fibrils. FEBS Lett. 2009, 583:2600-2609.
146. Lashuel H.A., Petre B.M., Wall J., Simon M., Nowak R.J., Walz T., Lansbury P.T. α-Synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 2002, 322:1089-1102.
147. Laurén J., Gimbel D.A., Nygaard H.B., Gilbert J.W., Strittmatter S.M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009, 457:1128-1132.
148. Lee S.J., Liyanage U., Bickel P.E., Xia W., Lansbury P.T., Kosik K.S. A detergent-insoluble membrane compartment contains Aβ in vivo. Nat. Med. 1998, 4:730-734.
149. Lee G., Pollard H.B., Arispe N. Annexin 5 and apolipoprotein E2 protect against Alzheimer's amyloid-β-peptide cytotoxicity by competitive inhibition at a common phosphatidylserine interaction site. Peptides 2002, 23:1249-1263.
150. Lee S., Fernandez E.J., Good T.A. Role of aggregation conditions in the structure, stability, and toxicity of intermediates in the Aβ fibril formation pathway. Protein Sci. 2007, 16:723-732.
151. Lesné S., Koh M.T., Kotlinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. A specific amyloid-β protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
152. Lin M.C., Mirzabekov T., Kagan B.L. Channel formation by a neurotoxic prion protein fragment. J. Biol. Chem. 1997, 272:44-47.
153. Lin H., Bhatia R., Lal R. Amyloid β protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J. 2001, 15:2433-2444.
154. Litvinovich S.V., Brew S.A., Aota S., Akiyama S.K., Haudenschild C., Ingham K.C. Formation of amyloid-like fibrils by self-association of a partially unfolded fibronectin type III module. J. Mol. Biol. 1998, 280:245-258.
155. Lomas D.A., Carrell R.W. Serpinopathies and the conformational dementias. Nat. Rev. Genet. 2002, 3:759-768.
156. Lührs T., Zahn R., Wüthrich K. Amyloid formation by recombinant full-length prion proteins in phospholipid bicelle solutions. J. Mol. Biol. 2006, 357:833-841.
157. Malchiodi-Albedi F., Contrusciere V., Raggi C., Fecch i K., Rainaldi G., Paradisi S., Matteucci A., Santini M.T., Sargiacomo M., Frank C., Gaudiano M.C., Diociaiuti M. Lipid rafts disruption protects mature neurons against amyloid oligomer toxicity. Biochim. Biophys. Acta 2010, 1802:406-415.
158. Mamikonyan G., Necula M., Mkrtichyan M., Ghochikyan A., Petrushina I., Movsesyan N., Mina E., Kiyatkin A., Glabe C.G., Cribbs D.H., Agadjanyan M.G. Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J. Biol. Chem. 2007, 282:22376-22386.
159. Martins I.C., Kuperstein I., Wilkinson H., Maes E., Vambrabant M., Jonckheere W., Van Gelder P., Hartmann D., D'Hooge R., De Strooper B., Schymkowitz J., Rousseau F. Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J. 2008, 27:224-233.
160. Mason R.P., Shoemaker W.J., Shajenko L., Chambers T.E., Herbette L.G. Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. Neurobiol. Aging 1992, 13:413-419.
161. Masters C.L., Simms G., Weinman N.A. Amyloid plaque core protein in Alzheimer's disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 1985, 82:4245-4249.
162. Masuda Y., Uemura S., Ohashi R., Nakanishi A., Takegoshi K., Shimizu T., Shirasawa T., Irie K. Identification of physiological and toxic conformations in Aβ42 aggregates. Chem. Biol. Chem. 2009, 10:287-295.
163. Matsuzaki K., Kato K., Yanagisawa K. Abeta polymerization through interaction with membrane gangliosides. Biochim. Biophys. Acta 2010, 1801:868-877.
164. Mattson M.P. Impairment of membrane transport and signal transduction systems by amyloidogenic proteins. Methods Enzymol. 1999, 309:733-768.
165. Meyer-Luheman M., Coomaraswamy J., Bolmont T., Kaeser S., Schaefer C., Kilger E., Neuenschwander A., Abramowski D., Frey P., Jaton A.J., Vigouret J.-M., Paganetti P., Walsh D.M., Mathews P.M., Ghiso J., Staufenbiel M., Walker L.C., Jucker M. Exogeneous induction of cerebral β-amyloidogenesis is governed by agent and host. Science 2006, 313:1781-1784.
166. Myers R.H., MacDonald M.E., Koroshetz W.J., Duyao M.P., Ambrose C.M., Taylor S.A.M., Barnes G., Srinidhi J., Lin C.S., Whaley W.L., Lazzarini A.M., Schwarz M., Wolff G., Bird E.D., Vonsattel J.-P.G., Gusella J.F. De novo expansion of a (CAG)n repeat in sporadic Huntington's disease. Nat. Genet. 1993, 5:168-173.
167. Mclaurin J.T., Fraser P.E., Chakrabartty A. Structural transitions associated with the interaction of Alzheimer's β-amyloid peptides with gangliosides. J. Biol. Chem. 1998, 273:4506-4515.
168. McParland V.J., Kad N.M., Kalverda A.P., Brown A., Kirwin-Jones P., Hunter M.G., Sunde M., Radford S.E. Partially unfolded states of beta(2)-microglobulin and amyloid formation in vitro. Biochemistry 2000, 39:8735-8746.
169. McParland V.J., Kalverda A.P., Homans S.W., Radford S.E. Structural properties of an amyloid precursor of beta(2)-microglobulin. Nat. Struct. Biol. 2002, 9:326-331.
170. Meinhardt J., Sachse C., Hortschansky P., Grigorieff N., Fandrich M. Abeta(1-40) fibril polymorphism implies diverse interaction patterns in amyloid fibrils. J. Mol. Biol. 2009, 386:869-877.
171. Milhavet O., Lehmann S. Oxidative stress and the prion protein in transmissible spongiform encephalopathies. Brain Res. Rev. 2002, 38:328-339.
172. Minton A.P. Influence of macromolecular crowding on intracellular association reactions: possible role in volume regulation. Cellular and Molecular Physiology of Cell Volume Regulation 1994, 181-190. CRC Press, Boca Raton, FL. K. Strange (Ed.).
173. Mirzabekov T.A., Lin M.C., Kagan B.L. Pore formation by the cytotoxic islet amyloid peptide amylin. J. Biol. Chem. 1996, 271:1988-1992.
174. Modler A.J., Gast K., Lutsch G., Damaschun G. Assembly of amyloid protofibrils via critical oligomers - a novel pathway of amyloid formation. J. Mol. Biol. 2003, 325:135-148.
175. Molander-Melin M., Blennow K., Bogdanovic N., Dellheden B., Månsson J.E., Fredman P. Structural membrane alterations in Alzheimer brains found to be associated with regional disease development, increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J. Neurochem. 2005, 92:171-182.
176. Monsellier E., Ramazzotti M., Taddei N., Chiti F. A computational approach for identifying the chemical factors involved in the glycosaminoglycans-mediated acceleration of amyloid fibril formation. PLoS ONE 2010, 5:e11363.
177. Monteiro F.A., Cardoso I., Mendes Sousa M., Saraiva M.J. In vitro inhibition of transthyretin aggregate-induced cytotoxicity by full and peptide derived forms of the soluble receptor for advanced glycation end products (RAGE). FEBS Lett. 2006, 580:3451-3456.
178. Morishima Y., Gotoh Y., Zieg J., Barrett T., Takano H., Flavell R., Davis R.J., Shirasaki Y., Greenberg M.E. Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J. Neurosci. 2001, 21:7551-7560.
179. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000, 20:4050-4058.
180. Mustata M., Capone R., Jang H., Arce F.T., Ramachandran S., Lal R., Nussinov R. K3 fragment of amyloidogenic beta(2)-microglobulin forms ion channels: implication for dialysis related amyloidosis. J. Am. Chem. Soc. 2009, 131:14938-14945.
181. Nandi P.K., Nicole J.-C. Nucleic acid and prion protein interaction produces spherical amyloids which can function in vivo as coats of spongiform encephalopathy agent. J. Mol. Biol. 2004, 344:827-837.
182. Necula M., Chirita C., Kuret J. Rapid anionic micelle-mediated α-synuclein fibrillization in vitro. J. Biol. Chem. 2002, 278:46674-46680.
183. Necula M., Kayed R., Milton S., Glabe C.G. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J. Biol. Chem. 2007, 282:10311-10324.
184. Nekooki-Machida Y., Kurosawa M., Nukina N., Ito K., Oda T., Tanaka M. Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:9679-9684.
185. Nguyen P.H., Li M.S., Stock G., Straub J.E., Thirumalai D. Monomer adds to preformed oligomers of Abeta peptides by a two-stage dot-lock mechanism. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:111-116.
186. Nilsberth C., Westlind-Danielssnon A., Eckman C.B., Condron M.M., Axelman K., Forsell C., Stenh C., Luthman J., Teplow D.B., Younkin S.G., Naslund J., Lannfelt L. The arctic APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation. Nat. Neurosci. 2001, 4:887-893.
187. Novitskaya V., Bocharova O.V., Bronstein I., Baskakov I.V. Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. J. Biol. Chem. 2006, 281:13828-13836.
188. O'Nuallain B., Wetzel R. Conformational Abs recognizing a generic amyloid fibril epitope. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:1485-1490.
189. Oliveira C.L., Behrens M.A., Pedersen J.S., Erlacher K., Otzen D., Pedersen J.S. A SAXS study of glucagon fibrillation. J. Mol. Biol. 2009, 387:147-161.
190. Orte A., Birkett N.R., Clarke R.W., Devlin G.L., Dobson C.M., Klenerman D. Direct characterization of amyloidogenic oligomers by single-molecule fluorescence. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:14424-14429.
191. 2+ increase in primary neuronal cells. J. Biol. Chem. 2008, 283:29950-29960.
192. Peng S., Glennert J., Westermark P. Medin-amyloid: a recently characterized age-associated arterial amyloid form affects mainly arteries in the upper part of the body. Amyloid 2005, 12:96-102.
193. Petkova A.T., Leapman R.D., Guo Z., Yau W.-M., Mattson M.P., Tycko R. Self-propagating, molecular level polymorphism in Alzheimer's β-amyloid fibrils. Science 2005, 307:262-265.
194. Petty S.A., Decatur S.M. Experimental evidence for the reorganization of beta strands within aggregates of the Abeta (16-22) peptide. J. Am. Chem. Soc. 2005, 127:13488-13489.
195. Plakoutsi G., Bemporad F., Calamai M., Taddei N., Dobson C.M., Chiti F. Evidence for a mechanism of amyloid formation involving molecular reorganisation within native-like precursor aggregates. J. Mol. Biol. 2005, 351:910-922.
196. Poirier M.A., Li H., Macosko J., Cail S., Amzel M., Ross C.A. Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrillization. J. Biol. Chem. 2002, 277:41032-41037.
197. Porat Y., Kolusheva S., Jelinek R., Gazit E. The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies. Biochemistry 2003, 42:10971-10977.
198. Pountney D.L., Voelcker N.H., Gai W.P. Annular α-synuclein oligomers are potentially toxic agents in α-synucleinopathy. Neurotox. Res. 2005, 7:59-67.
199. Prusiner S.B., Scott M.R., deArmond S.J., Cohen F.E. Prion protein biology. Cell 1998, 93:337-348.
200. Puchtler H., Sweat F. A review of early concepts of amyloid in context with contemporary chemical literature from 1839 to 1859. J. Histochem. Cytochem. 1965, 14:123-135.
201. Qui L., Buie C., Reay A., Vaughn M.W., Cheng K.H. Molecular dynamics simulation reveal the protective role of cholesterol in β-amyloid protein-induced membrane disruptions in neuronal membrane mimics. J. Phys. Chem. 2011, 115:9795-9812.
202. Quintas A., Vaz D.C., Cardoso I., Saraiva M.J.M., Brito R.M.M. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J. Biol. Chem. 2001, 276:27207-27213.
203. Ran S., Thorpe P.E. Phosphatidylserine is a marker of tumour vasculature and a potential target for cancer imaging and therapy. Int. J. Radiat. Oncol. Biol. Phys. 2002, 54:1479-1484.
204. Relini A., Torrassa S., Rolandi R., Gliozzi A., Rosano C., Canale C., Bolognesi M., Plakoutsi G., Bucciantini M., Chiti F., Stefani M. Monitoring the process of HypF fibrillization and liposome permeabilization by protofibrils. J. Mol. Biol. 2004, 338:943-957.
205. Relini A., Canale C., De Stefano S., Rolandi R., Giorgetti S., Stoppini M., Rossi A., Fogolari F., Corazza A., Esposito G., Gliozzi A., Bellotti V. Collagen plays an active role in the aggregation of beta2-microglobulin under physiopathological conditions of dialysis-related amyloidosis. J. Biol. Chem. 2006, 281:16521-16529.
206. Romero P., Obradovich Z., Kissinger C., Villafranca J.E., Garner E., Guilliot S., Bunker A.K. Thousands of proteins likely to have long disordered regions. Pac. Symp. Biocomput. 1998, 3:437-448.
207. Ross C.A. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 2002, 35:819-822.
208. Rousseau F., Serrano L., Schymkowitz J.W.H. How evolutionary pressure against protein aggregation shaped chaperone specificity. J. Mol. Biol. 2006, 355:1037-1047.
209. Rousseau F., Wilkinson H., Villanueva J., Serrano L., Schymkowitz J.W., Itzhaki L.S. Domain swapping in p13suc1 results in formation of native-like, cytotoxic aggregates. J. Mol. Biol. 2006, 363:496-505.
210. Rushworth J.V., Hooper N.M. Lipid rafts: linking Alzheimer's amyloid-β production, aggregation, and toxicity at neuronal membranes. Int. J. Alzheimers Dis. 2010, 2011:603052.
211. c association with lipid rafts in the early secretory pathway stabilizes its cellular conformation. Mol. Biol. Cell 2004, 15:4031-4042.
212. Sasaki N., Takeuchi M., Chowei H., Kikuchi S., Hayashi N., Nakano H., Ikeda S., Yamagishi T., Kitamoto T., Saito T., Makita Z. Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques. Neurosci. Lett. 2002, 326:117-120.
213. Schubert D., Behl C., Lesley R., Brack A., Dargusch R., Sagara Y., Kimura H. Amyloid peptides are toxic via a common oxidative mechanism. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:1989-1993.
214. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 1991, 6:487-498.
215. Selkoe D.J. Folding proteins in fatal ways. Nature 2003, 426:900-904.
216. Serag A.A., Altenbach C., Gingery M., Hubbell W.L., Yeates T.O. Arrangement of subunits and ordering of beta-strands in an amyloid sheet. Nat. Struct. Biol. 2002, 9:734-739.
217. Serio T.R., Cashikar A.G., Kowal A.S., Sawicki G.J., Moslehi J.J., Serpell L., Arnsdorf M.F., Lindquist S. Nucleated conformation conversion and the replication of conformational information by a prion determinant. Science 2000, 289:1317-1321.
218. Serpell L.C., Sunde M., Benson M.D., Tennent G.A., Pepys M.B., Fraser P.E. The protofilament substructure of amyloid fibrils. J. Mol. Biol. 2000, 300:1033-1039.
219. Sethuraman A., Belfort G. Protein structural perturbation and aggregation on homogeneous surfaces. Biophys. J. 2005, 88:1322-1333.
220. Shadek G.M., Kummer M.P., Lu D.C., Galvan V., Bredesen D.E., Koo E.H. Aβ induces cell death by direct interaction with its cognate extracellular domain on APP (APP 597-624). FASEB J. 2006, 20:1254-1266.
221. Shankar G.M., Leissring M.A., Adame A., Sun X., Spooner E., Masliah E., Selkoe D.J., Lemere C.A., Walsh D.M. Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Aβ assembly forms throughout life. Neurobiol. Dis. 2009, 36:293-302.
222. Simons K., Ehahalt R. Cholesterol, lipid rafts, and disease. J. Clin. Invest. 2002, 110:597-603.
223. Sipe J.D., Benson M.D., Buxbaum J.N., Ikeda S., Merlini G., Saraiva M.J., Westermark P. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid 2010, 17(3-4):101-104.
224. Sirangelo I., Malmo C., Iannuzzi C., Mezzogiorno A., Bianco M.R., Papa M., Irace G. Fibrillogenesis and cytotoxic activity of the amyloid-forming apomyoglobin mutant W7FW14F. J. Biol. Chem. 2004, 279:13183-13189.
225. Smith A.M., Jahn T.R., Ashcroft A.E., Radford S.E. Direct observation of oligomeric species formed in the early stages of amyloid fibril formation using electrospray ionisation mass spectrometry. J. Mol. Biol. 2006, 364:9-19.
226. Smith J.F., Knowles T.P.J., Dobson C.M., MacPhee C.E., Welland M.E. Characterization of the nanoscale properties of individual amyloid fibrils. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:15806-15811.
227. Sousa M.M., Cardoso I., Fernandes R., Guimaraes A., Saraiva M.J. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy. Am. J. Pathol. 2001, 159:1993-2000.
228. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., Goedert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:6469-6473.
229. Squier T.C. Oxidative stress and protein aggregation during biological aging. Exp. Gerontol. 2001, 36:1539-1550.
230. Stefani M. Generic cell dysfunction in neurodegenerative disorders: role of surfaces in early protein misfolding, aggregation, and aggregate cytotoxicity. The Neuroscientist 2007, 13:519-531.
231. Stefani M., Dobson C.M. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 2003, 81:678-699.
232. Stefani M., Liguri G. Cholesterol in Alzheimer's disease: unresolved questions. Curr. Alz. Res. 2009, 6:15-29.
233. Suk J.Y., Zhang F., Balch W.E., Linhardt R.J., Kelly J.W. Heparin accelerates gelsolin amyloidogenesis. Biochemistry 2006, 45:2234-2242.
234. Svanborg C., Agerstam H., Aronson A., Bjerkvig R., Duringer C., Fischer W., Gustafsson L., Hallgren O., Leijonhuvud I., Linse S., Mossberg A.-K., Nilsson H., Pettersson J., Svensson M. HAMLET kills tumor cells by an apoptosis-like mechanism - cellular, molecular, and therapeutic aspects. Adv. Cancer Res. 2003, 88:1-29.
235. Townsend M., Shankar G.M., Mehta T., Walsh D.M., Selkoe D.J. Effects of secreted oligomers on amyloid β-protein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol. 2006, 572(2):477-492.
236. Utsugi T., Schroit A.J., Connor J., Bucana C.D., Fidler I.J. Elevated expression of phosphatidylserine inn the outer membrane leaflet of human tumour cells and recognition by activated human blood monocytes. Cancer Res. 1991, 51:3062-3066.
237. Uversky V.N. Natively unfolded proteins: a point where biology waits for physics. Protein Sci. 2002, 11:739-756.
238. Uversky V.N., Li J., Fink A.L. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem. 2001, 276:10737-10744.
239. Varadarajan S., Yatin S., Aksenova M., Butterfield D.A. Alzheimer's amyloid β-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 2000, 130:184-208.
240. Velez-Pardo C., Arroyave S.T., Lopera F., Castano A.D., Jimenez Del Rio M. Ultrastructure evidence of necrotic neural cell death in familial Alzheimer's disease brains bearing presenilin-1 E280A mutation. J. Alzheimers Dis. 2001, 3:409-415.
241. Volles M.J., Lansbury P.T. Vesicle permeabilization by protofibrillar α-synuclein: comparison of wild-type with Parkinson's disease linked mutants and insights in the mechanisms. Biochemistry 2001, 40:7812-7819.
242. Wakabayashi M., Matsuzaki K. Formation of amyloids by Abeta-(1-42) on NGF-differentiated PC12 cells: roles of gangliosides and cholesterol. J. Mol. Biol. 2007, 371:924-933.
243. Wakabayashi M., Matsuzaki K. Ganglioside-induced amyloid formation by human islet amyloid polypeptide in lipid rafts. FEBS Lett. 2009, 583:2854-2858.
244. Walsh D.M., Selkoe D.J. Oligomers in the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein peptide Lett. 2004, 11:213-228.
245. Walsh D.M., Tseng B.P., Rydel R.E., Podlisny M.B., Selkoe D.J. The oligomerization of amyloid β-protein begins intracellularly in cell derived from human brain. Biochemistry 2000, 39:10831-10839.
246. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
247. Watt J.A., Pike C.J., Walencewicz-Wasserman A.J., Cotman C.W. Ultrastructural analysis of beta-amyloid-induced apoptosis in cultured hippocampal neurons. Brain Res. 1994, 661:147-156.
248. Wiseman R.L., Powers E.T., Kelly J.W. Partitioning conformational intermediates between competing refolding and aggregation pathways: insights into transthyretin amyloid disease. Biochemistry 2005, 44:16612-16623.
249. Wright P.E., Dyson H.J. Intrinsically unstructured proteins: reassessing the protein structure-function paradigm. J. Mol. Biol. 1999, 293:321-331.
250. Xue W.-F., Hellewell A.L., Gosal W.S., Homans S.W., Hewitt E.W., Radford S.E. Fibril fragmentation enhances amyloid cytotoxicity. J. Biol. Chem. 2009, 284:34272-34282.
251. Yamamoto N., Matsubara T., Sato T., Yanagisawa K. Age-dependent high-density clustering of GM1 ganglioside at presynaptic neuritic terminals promotes amyloid β-protein fibrillogenesis. Biochim. Biophys. Acta 2008, 1778:2717-2726.
252. Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhan M., Nagashima J., Morser A., Migheli P., Nawroth D., Stern A.M., Schmidt A.M. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996, 382:685-691.
253. Yan S.D., Stern D., Kane M.D., Kuo Y.M., Lampert H.C., Roher A.E. RAGE-Abeta interactions in the pathophysiology of Alzheimer's disease. Restor. Neurol. Neurosci. 1998, 12:167-173.
254. Yan S.D., Zhu H., Zhu A., Golabek A., Du H., Roher A., Yu J., Soto C., Schmidt A.M., Stern D., Kindy M. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat. Med. 2000, 6:643-651.
255. Yankner B.A., Caceres A., Daffy L.K. Nerve growth factor potentiates the neurotoxicity of β amyloid. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:9020-9023.
256. Yip C.M., Elton E.A., Darabie A.A., Morrison M.R., McLaurin J. Cholesterol, a modulator of membrane-associated Aβ-fibrillogenesis and neurotoxicity. J. Mol. Biol. 2001, 311:723-734.
257. Yoshiike Y., Kayed R., Milton S.C., Takashima A., Glabe C.G. Pore-forming proteins share structural and functional homology with amyloid oligomers. Neuromolecular Med. 2007, 9:270-275.
258. Yuyama K., Yanagisawa K. Sphingomyelin accumulation provides a favorable milieu for GM1 ganglioside-induced assembly of amyloid β-protein. Neurosci. Lett. 2010, 481:168-172.
259. Zampagni M., Cascella R., Casamenti F., Grossi C., Evangelisti E., Wright D., Becatti M., Liguri G., Mannini B., Campioni S., Chiti F., Cecchi C. A comparison of the biochemical modifications caused by toxic and non-toxic protein oligomersmin cells. J. Cell. Mol. Med. 2011, 15:2106-2116.
260. Zhang Y.-H., Leliveld S.R., Kooistra K., Molenaar C., Rohn J.L., Tanke H.J., Abrahams J.P., Noteborn M.H.M. Recombinant apoptin multimers kill tumor cells but are non-toxic and epitope-shielded in a normal-cell-specific fashion. Exp. Cell Res. 2003, 289:36-46.
261. Zhao H., Tuominen E.K.J., Kinnunen P.K.J. Formation of amyloid fibers triggered by phosphatidylserine-containing membranes. Biochemistry 2004, 43:10302-10307.
262. Zhao H., Jutila A., Nurminen T., Wickström S.A., Keski-Oja J., Kinnunen P.K.J. Binding of endostatin to phosphatidylserine-containing membranes and formation of amyloid-like fibers. Biochemistry 2005, 44:2857-2863.
263. Zhu Y.J., Lin H., Lal R. Fresh and nonfibrillar amyloid β protein (1-40) induces rapid cellular degeneration in aged human fibroblasts: evidence for AβP-channel-mediated cellular toxicity. FASEB J. 2000, 14:1244-1254.
264. Zhu M., Souillac P.O., Ionesco-Zanetti C., Carter S.A., Fink A.L. Surface-catalyzed amyloid fibril formation. J. Biol. Chem. 2002, 277:50914-50922.